4,2',4',6'-Tetrahydroxychalcone
CAS 25515-46-2
4,2',4',6'-Tetrahydroxychalcone (CAS 25515-46-2) is a pharmaceutical compound with 5 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 24326.3625 nM | 16 | - |
| - | IC50 | 65183.333333333336 nM | 6 | - |
| - | MIC | 666666.6666666666 nM | 3 | - |
| - | EC50 | 4000 nM | 1 | - |
| - | Kd | 4800 nM | 1 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is 4,2',4',6'-Tetrahydroxychalcone used for in pharmaceutical contexts?
4,2',4',6'-Tetrahydroxychalcone (CAS 25515-46-2) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for 4,2',4',6'-Tetrahydroxychalcone?
No adverse-event association or SIDER side-effect rows are rendered for 4,2',4',6'-Tetrahydroxychalcone in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is 4,2',4',6'-Tetrahydroxychalcone also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Naringenin Chalcone with EU status "permitted".
What clinical phase is 4,2',4',6'-Tetrahydroxychalcone in?
No phase 1-4 clinical development badge is rendered for 4,2',4',6'-Tetrahydroxychalcone because the matched compound identifier rows do not contain a max-phase value.